Topical Combo based on Pfizer and Novartis Drugs advances after Clearing early Clinical test
Synopsis: Pfizer’s JAK inhibitor Xeljanz and Novartis’ S1P modulator Gilenya both have their share of safety problems. But Vyne Therapeutics thinks it…
Synopsis: Pfizer’s JAK inhibitor Xeljanz and Novartis’ S1P modulator Gilenya both have their share of safety problems. But Vyne Therapeutics thinks it…